Tempest Therapeutics, Inc. (TPST) · Nov 20, 2026 · Delisting
Delisting notice — Failed capital raise required to restore stockholders’ equity above $2.5M
Tempest Therapeutics received a Nasdaq delisting notice after failing to complete the capital raise needed to restore equity compliance; an appeal now buys time.
Tempest is a cash-constrained clinical-stage biotech trying to advance an in vivo CAR-T pipeline for cancer and autoimmune disease; as of September 30, 2026, it had only $0.9 million of cash, a $1.8 million stockholders’ deficit, and substantial doubt about continuing as a going concern.
The financing problem has become an actual listing threat. Nasdaq had given Tempest until November 16, 2026 to restore the $2.5 million minimum-equity requirement, but the company did not complete the required capital raise. 〔0〕 That is materially worse than the earlier deficiency notice: the company has moved from needing financing to preserve its listing to receiving a formal delisting determination.
The appeal preserves trading access, not the underlying fix. Tempest plans to request a Nasdaq Hearings Panel hearing, which should stay any immediate suspension or delisting while the appeal proceeds. 〔1〕 But the filing offers no completed financing, equity repair, or alternative compliance solution; it explicitly says the company cannot assure a successful appeal. The stay therefore buys roughly one procedural window rather than resolving the capital shortfall.
This undercuts the company’s recently presented funding story. Its November 13 update highlighted a potential equity line of up to $50 million and an approximately $2.5 million private placement, but the subsequent filing confirms that the capital raise needed for Nasdaq compliance was not completed. Against a business already dependent on external capital, losing certainty around financing also complicates the ability to keep advancing clinical programs.
Bottom line: This is a clear deterioration in Tempest’s operating and financing situation, not merely a routine Nasdaq notice. The appeal delays the consequence, but the company still needs fresh capital and a successful hearing to preserve its current listing.
Nasdaq Hearings Panel appeal, typically within 30–45 days
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!